Compile Data Set for Download or QSAR
Report error Found 202 Enz. Inhib. hit(s) with all data for entry = 9928
TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283363BDBM283363(US10023557, Example 15 | N-((6-amino-2,4-dimethylp...)
Affinity DataEC50: <100nMAssay Description:Materials:Plasma kallikrein inhibitor C1NH (Athens Research & Technology, Cat #16-16-031509); Ellagic acid (Sigma, E2250); Substrate Z-FR-2-AMC (GL B...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283493BDBM283493(US10023557, Example 145 | N-((6-amino-2,4-dimethyl...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283492BDBM283492(US10023557, Example 144 | N-((6-amino-2,4-dimethyl...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283491BDBM283491(US10023557, Example 143 | N-((3-chloro-6-fluoro-1H...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283490BDBM283490(US10023557, Example 142 | N-((1-aminoisoquinolin-6...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283489BDBM283489(US10023557, Example 141 | N-((6-amino-2,4-dimethyl...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283488BDBM283488(US10023557, Example 140 | N-((3-chloro-6-fluoro-1H...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283487BDBM283487(US10023557, Example 139 | N-((1-aminoisoquinolin-6...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 378009BDBM378009(US10308637, Example 138 | US10266515, Example 138 ...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283484BDBM283484(US10023557, Example 136 | N-((1-aminoisoquinolin-6...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283481BDBM283481(US10023557, Example 133 | N-((3-chloro-6-fluoro-1H...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283480BDBM283480(US10023557, Example 132 | N-((1-aminoisoquinolin-6...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283398BDBM283398(US10023557, Example 50 | N-((6-amino-2,4-dimethylp...)
Affinity DataEC50: <100nMAssay Description:Materials:Plasma kallikrein inhibitor C1NH (Athens Research & Technology, Cat #16-16-031509); Ellagic acid (Sigma, E2250); Substrate Z-FR-2-AMC (GL B...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283382BDBM283382(US10023557, Example 34 | N-((6-amino-2-methylpyrid...)
Affinity DataEC50: <100nMAssay Description:Materials:Plasma kallikrein inhibitor C1NH (Athens Research & Technology, Cat #16-16-031509); Ellagic acid (Sigma, E2250); Substrate Z-FR-2-AMC (GL B...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283383BDBM283383(US10023557, Example 35 | N-((6-amino-2,4-dimethylp...)
Affinity DataEC50: <100nMAssay Description:Materials:Plasma kallikrein inhibitor C1NH (Athens Research & Technology, Cat #16-16-031509); Ellagic acid (Sigma, E2250); Substrate Z-FR-2-AMC (GL B...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283382BDBM283382(US10023557, Example 34 | N-((6-amino-2-methylpyrid...)
Affinity DataEC50: <100nMAssay Description:Materials:Plasma kallikrein inhibitor C1NH (Athens Research & Technology, Cat #16-16-031509); Ellagic acid (Sigma, E2250); Substrate Z-FR-2-AMC (GL B...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283379BDBM283379(N-((1-aminoisoquinolin-6-yl)methyl)-2-((3- chloroq...)
Affinity DataEC50: <100nMAssay Description:Materials:Plasma kallikrein inhibitor C1NH (Athens Research & Technology, Cat #16-16-031509); Ellagic acid (Sigma, E2250); Substrate Z-FR-2-AMC (GL B...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283369BDBM283369(US10023557, Example 21 | N-((3-chloro-4-fluoro-1H-...)
Affinity DataEC50: <100nMAssay Description:Materials:Plasma kallikrein inhibitor C1NH (Athens Research & Technology, Cat #16-16-031509); Ellagic acid (Sigma, E2250); Substrate Z-FR-2-AMC (GL B...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283368BDBM283368(US10023557, Example 20 | N-((5-chloro-1H-indazol-3...)
Affinity DataEC50: <100nMAssay Description:Materials:Plasma kallikrein inhibitor C1NH (Athens Research & Technology, Cat #16-16-031509); Ellagic acid (Sigma, E2250); Substrate Z-FR-2-AMC (GL B...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283367BDBM283367(US10023557, Example 19 | N-((3-chloro-1H-pyrrolo[2...)
Affinity DataEC50: <100nMAssay Description:Materials:Plasma kallikrein inhibitor C1NH (Athens Research & Technology, Cat #16-16-031509); Ellagic acid (Sigma, E2250); Substrate Z-FR-2-AMC (GL B...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283365BDBM283365(US10023557, Example 17 | N-((3-chloro-6-fluoro-1H-...)
Affinity DataEC50: <100nMAssay Description:Materials:Plasma kallikrein inhibitor C1NH (Athens Research & Technology, Cat #16-16-031509); Ellagic acid (Sigma, E2250); Substrate Z-FR-2-AMC (GL B...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283364BDBM283364(US10023557, Example 16 | N-((1-aminoisoquinolin-6-...)
Affinity DataEC50: <100nMAssay Description:Materials:Plasma kallikrein inhibitor C1NH (Athens Research & Technology, Cat #16-16-031509); Ellagic acid (Sigma, E2250); Substrate Z-FR-2-AMC (GL B...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283425BDBM283425(US10023557, Example 77 | 6-((4-(((6-amino-2,4-dime...)
Affinity DataEC50: <100nMAssay Description:Materials:Plasma kallikrein inhibitor C1NH (Athens Research & Technology, Cat #16-16-031509); Ellagic acid (Sigma, E2250); Substrate Z-FR-2-AMC (GL B...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283419BDBM283419(US10023557, Example 71 | N-((1-aminoisoquinolin-6-...)
Affinity DataEC50: <100nMAssay Description:Materials:Plasma kallikrein inhibitor C1NH (Athens Research & Technology, Cat #16-16-031509); Ellagic acid (Sigma, E2250); Substrate Z-FR-2-AMC (GL B...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283418BDBM283418(US10023557, Example 70 | N-((6-amino-2,4-dimethylp...)
Affinity DataEC50: <100nMAssay Description:Materials:Plasma kallikrein inhibitor C1NH (Athens Research & Technology, Cat #16-16-031509); Ellagic acid (Sigma, E2250); Substrate Z-FR-2-AMC (GL B...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283417BDBM283417(US10023557, Example 69 | N-((6-amino-2-methylpyrid...)
Affinity DataEC50: <100nMAssay Description:Materials:Plasma kallikrein inhibitor C1NH (Athens Research & Technology, Cat #16-16-031509); Ellagic acid (Sigma, E2250); Substrate Z-FR-2-AMC (GL B...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283416BDBM283416(US10023557, Example 68 | N-((3-chloro-6-fluoro-1H-...)
Affinity DataEC50: <100nMAssay Description:Materials:Plasma kallikrein inhibitor C1NH (Athens Research & Technology, Cat #16-16-031509); Ellagic acid (Sigma, E2250); Substrate Z-FR-2-AMC (GL B...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283415BDBM283415(US10023557, Example 67 | N-((6-amino-2,4-dimethylp...)
Affinity DataEC50: <100nMAssay Description:Materials:Plasma kallikrein inhibitor C1NH (Athens Research & Technology, Cat #16-16-031509); Ellagic acid (Sigma, E2250); Substrate Z-FR-2-AMC (GL B...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283413BDBM283413(US10023557, Example 65 | 3-chloro-6-((4-(((3-chlor...)
Affinity DataEC50: <100nMAssay Description:Materials:Plasma kallikrein inhibitor C1NH (Athens Research & Technology, Cat #16-16-031509); Ellagic acid (Sigma, E2250); Substrate Z-FR-2-AMC (GL B...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283412BDBM283412(US10023557, Example 64 | 6-((4-(((1-aminoisoquinol...)
Affinity DataEC50: <100nMAssay Description:Materials:Plasma kallikrein inhibitor C1NH (Athens Research & Technology, Cat #16-16-031509); Ellagic acid (Sigma, E2250); Substrate Z-FR-2-AMC (GL B...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283410BDBM283410(US10023557, Example 62 | 6-((4-(((6-amino-2-methyl...)
Affinity DataEC50: <100nMAssay Description:Materials:Plasma kallikrein inhibitor C1NH (Athens Research & Technology, Cat #16-16-031509); Ellagic acid (Sigma, E2250); Substrate Z-FR-2-AMC (GL B...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283406BDBM283406(US10023557, Example 58 | 6-((4-(((6-amino-2,4-dime...)
Affinity DataEC50: <100nMAssay Description:Materials:Plasma kallikrein inhibitor C1NH (Athens Research & Technology, Cat #16-16-031509); Ellagic acid (Sigma, E2250); Substrate Z-FR-2-AMC (GL B...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283463BDBM283463(US10023557, Example 115 | N-((1-aminoisoquinolin-6...)
Affinity DataEC50: <100nMAssay Description:Materials:Plasma kallikrein inhibitor C1NH (Athens Research & Technology, Cat #16-16-031509); Ellagic acid (Sigma, E2250); Substrate Z-FR-2-AMC (GL B...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283462BDBM283462(US10023557, Example 114 | N-((6-amino-2,4-dimethyl...)
Affinity DataEC50: <100nMAssay Description:Materials:Plasma kallikrein inhibitor C1NH (Athens Research & Technology, Cat #16-16-031509); Ellagic acid (Sigma, E2250); Substrate Z-FR-2-AMC (GL B...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283461BDBM283461(US10023557, Example 113 | N-((6-amino-2,4-dimethyl...)
Affinity DataEC50: <100nMAssay Description:Materials:Plasma kallikrein inhibitor C1NH (Athens Research & Technology, Cat #16-16-031509); Ellagic acid (Sigma, E2250); Substrate Z-FR-2-AMC (GL B...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283448BDBM283448(US10023557, Example 100 | N-((6-amino-2,4-dimethyl...)
Affinity DataEC50: <100nMAssay Description:Materials:Plasma kallikrein inhibitor C1NH (Athens Research & Technology, Cat #16-16-031509); Ellagic acid (Sigma, E2250); Substrate Z-FR-2-AMC (GL B...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283439BDBM283439(US10023557, Example 91 | N-((6-amino-2-methylpyrid...)
Affinity DataEC50: <100nMAssay Description:Materials:Plasma kallikrein inhibitor C1NH (Athens Research & Technology, Cat #16-16-031509); Ellagic acid (Sigma, E2250); Substrate Z-FR-2-AMC (GL B...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283437BDBM283437(US10023557, Example 89 | N-((6-amino-2,4-dimethylp...)
Affinity DataEC50: <100nMAssay Description:Materials:Plasma kallikrein inhibitor C1NH (Athens Research & Technology, Cat #16-16-031509); Ellagic acid (Sigma, E2250); Substrate Z-FR-2-AMC (GL B...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283432BDBM283432(US10023557, Example 84 | 6-((4-(((6-amino-2,4-dime...)
Affinity DataEC50: <100nMAssay Description:Materials:Plasma kallikrein inhibitor C1NH (Athens Research & Technology, Cat #16-16-031509); Ellagic acid (Sigma, E2250); Substrate Z-FR-2-AMC (GL B...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283428BDBM283428(US10023557, Example 80 | 6-((4-(((3-chloro-1H-pyrr...)
Affinity DataEC50: <100nMAssay Description:Materials:Plasma kallikrein inhibitor C1NH (Athens Research & Technology, Cat #16-16-031509); Ellagic acid (Sigma, E2250); Substrate Z-FR-2-AMC (GL B...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283427BDBM283427(US10023557, Example 79 | 6-((4-(((1-aminoisoquinol...)
Affinity DataEC50: <100nMAssay Description:Materials:Plasma kallikrein inhibitor C1NH (Athens Research & Technology, Cat #16-16-031509); Ellagic acid (Sigma, E2250); Substrate Z-FR-2-AMC (GL B...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283426BDBM283426(US10023557, Example 78 | 6-((4-(((3-chloro-6-fluor...)
Affinity DataEC50: <100nMAssay Description:Materials:Plasma kallikrein inhibitor C1NH (Athens Research & Technology, Cat #16-16-031509); Ellagic acid (Sigma, E2250); Substrate Z-FR-2-AMC (GL B...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283493BDBM283493(US10023557, Example 145 | N-((6-amino-2,4-dimethyl...)
Affinity DataEC50: <100nMAssay Description:Materials:Plasma kallikrein inhibitor C1NH (Athens Research & Technology, Cat #16-16-031509); Ellagic acid (Sigma, E2250); Substrate Z-FR-2-AMC (GL B...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283492BDBM283492(US10023557, Example 144 | N-((6-amino-2,4-dimethyl...)
Affinity DataEC50: <100nMAssay Description:Materials:Plasma kallikrein inhibitor C1NH (Athens Research & Technology, Cat #16-16-031509); Ellagic acid (Sigma, E2250); Substrate Z-FR-2-AMC (GL B...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283490BDBM283490(US10023557, Example 142 | N-((1-aminoisoquinolin-6...)
Affinity DataEC50: <100nMAssay Description:Materials:Plasma kallikrein inhibitor C1NH (Athens Research & Technology, Cat #16-16-031509); Ellagic acid (Sigma, E2250); Substrate Z-FR-2-AMC (GL B...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283466BDBM283466(US10023557, Example 118 | N-((1-aminoisoquinolin-6...)
Affinity DataEC50: <100nMAssay Description:Materials:Plasma kallikrein inhibitor C1NH (Athens Research & Technology, Cat #16-16-031509); Ellagic acid (Sigma, E2250); Substrate Z-FR-2-AMC (GL B...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283351BDBM283351(US10023557, Example 3 | N-((1-aminoisoquinolin-6-y...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283367BDBM283367(US10023557, Example 19 | N-((3-chloro-1H-pyrrolo[2...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283366BDBM283366(US10023557, Example 18 | N-((6-fluoro-1H-indol-5-y...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283365BDBM283365(US10023557, Example 17 | N-((3-chloro-6-fluoro-1H-...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

Displayed 1 to 50 (of 202 total ) | Next | Last >>
Jump to: